Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets

Genes Chromosomes and Cancer

Volumn 53, Issue 11, 2014, Pages 883-894

  Qian, Ziliang ^a   Zhu, Guanshan ^a   Tang, Lili ^a   Wang, Mei ^a   Zhang, Lianhai ^b   Fu, Jiangang ^a   Huang, Chunlei ^a   Fan, Shuqiong ^a   Sun, Yun ^a   Lv, Jing ^a   Dong, Hua ^a   Gao, Beirong ^a   Su, Xinying ^a   Yu, Dehua ^a   Zang, Jie ^a   Zhang, Xiaolin ^a   Ji, Jiafu ^b   Ji, Qunsheng ^a  

^a ASTRAZENECA   (United Kingdom)

^b CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; MESSENGER RNA; SELUMETINIB; BENZIMIDAZOLE DERIVATIVE; KRAS PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; ONCOPROTEIN; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN; RAS PROTEIN;

ABCC4 GENE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; CHINESE; CHROMOSOMAL INSTABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CTSB GENE; ERBB2 GENE; FEMALE; FGFR2 GENE; GASTRIC CANCER CELL LINE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MET GENE; MIDDLE AGED; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE K RAS; ONCOGENE PAK1; OVERALL SURVIVAL; PRIORITY JOURNAL; PRKCI GENE; STARD13 GENE; STOMACH CANCER; TREATMENT OUTCOME; TUMOR GENE; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; GENE DOSAGE; GENETICS; HUMAN GENOME; METABOLISM; MORTALITY; MUTATION; STOMACH TUMOR; SURVIVAL RATE;

BENZIMIDAZOLES; CHROMOSOMAL INSTABILITY; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MIDDLE AGED; MUTATION; P21-ACTIVATED KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84927570856     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22196     Document Type: Article

References (42)

1. Adachi Y, Kamakura T, Mori M, Baba H, Maehara Y, Sugimachi K. 1994. Prognostic significance of the number of positive lymph nodes in gastric carcinoma. Br J Surg 81:414-416.
2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697.
3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465.
4. Davies JJ, Wilson IM, Lam WL. 2005. Array CGH technologies and their applications to cancer genomes. Chromosome Res 13:237-248.
5. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD. 2007. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6:2209-2219.
6. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, Ricketts SA, Cross D, Cosulich S, Chresta CC, Page K, Yates J, Lane C, Watson R, Luke R, Ogilvie D, Pass M. 2012. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11:873-887.
7. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C. 2013. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24:1697-1703.
8. Deng J, Liang H, Sun D, Zhang R, Zhan H, Wang X. 2008. Prognosis of gastric cancer patients with node-negative metastasis following curative resection: outcomes of the survival and recurrence. Can J Gastroenterol 22:835-839.
9. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P. 2012. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673-684.
10. Fuchs CS, Mayer RJ. 1995. Gastric carcinoma. N Engl J Med 333:32-41.
11. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T. 2012. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 72:2045-2056.
12. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, Bose R, Ornitz D, Xiong D, You M, Dooling DJ, Watson M, Mardis ER, Wilson RK. 2012. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150:1121-1134.
13. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Clackson T, Rivera VM. 2012. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 11:690-699.
14. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, D.G. Haller M. 2002. American Joint Committee on Cancer: Gastric Cancer. AJCC Cancer Staging Manual, 5th ed, American Joint Committee on Cancer, USA.
15. Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, Chen Z, Wilson CJ, Bordas V, Le Douget M, Gaither LA, Borawski J, Monahan JE, Venkatesan K, Brummendorf T, Thomas DM, Garcia-Echeverria C, Hofmann F, Sellers WR, Graus-Porta D. 2012. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov 2:1118-1133.
16. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723.
17. Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer MB, Beer DG, Hanash S. 1998. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci USA 95:12410-12415.
18. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansen S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Janne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M. 2012. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107-1120.
19. Jiang JJ, Liu HY, Hao JK, Wang LN, Wang YP, Sun LH, Yuan Y. 2012. Gastric cancer incidence and mortality in Zhuanghe, China, between (2005) and (2010). World J Gastroenterol 18:1262-1269.
20. Keniry M, Parsons R. 2008. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27:5477-5485.
21. Kiyose S, Nagura K, Tao H, Igarashi H, Yamada H, Goto M, Maeda M, Kurabe N, Suzuki M, Tsuboi M, Kahyo T, Shinmura K, Hattori N, Sugimura H. 2012. Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. Pathol Int 62:477-484.
22. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO. 2011. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25:1517-1524.
23. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. 2012. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268-273.
24. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. 2011. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29:4803-4810.
25. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ. 2011. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 4(166):ra17.
26. Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, Nishio K, Yamada Y. 2012. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 106:727-732.
27. Mlkvy P. 2010. Multimodal therapy of gastric cancer. Dig Dis 28:615-618.
28. Network TCGA. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337.
29. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, Bazan V, Russo A. 2006. Patterns of genomic instability in gastric cancer: Clinical implications and perspectives. Ann Oncol 17 Suppl 7:vii97-102.
30. Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264.
31. Roukos DH. 2010. Targeting gastric cancer with trastuzumab: New clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14-17.
32. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. 2012. Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327-2333.
33. Sotoudeh K, Hashemi F, Madjd Z, Sadeghipour A, Molanaei S, Kalantary E. 2012. The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Diagn Pathol 7:57.
34. Suzuki K, Ohnami S, Tanabe C, Sasaki H, Yasuda J, Katai H, Yoshimura K, Terada M, Perucho M, Yoshida T. 2003. The genomic damage estimated by arbitrarily primed PCR DNA fingerprinting is useful for the prognosis of gastric cancer. Gastroenterology 125:1330-1340.
35. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454.
36. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110.
37. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, Cheng GH, Roberts PC, Rejto PA, Gibson NW, Pocalyko DJ, Mao M, Xu J, Leung SY. 2011. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43:1219-1223.
38. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113.
39. Wu CW, Hsieh MC, Lo SS, Tsay SH, Lui WY, P'Eng F K. 1996. Relation of number of positive lymph nodes to the prognosis of patients with primary gastric adenocarcinoma. Gut 38:525-527.
40. Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Ji J, Gavine PR, Zhang J, Kilgour E, Ji Q. 2013. FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547. Clin Cancer Res 19: 2572-2583.
41. Yang L. 2006. Incidence and mortality of gastric cancer in China. World J Gastroenterol 12:17-20.
42. Zhu X, Li J. 2010. Gastric carcinoma in China: Current status and future perspectives (Review). Oncol Lett 1:407-412.